Avalo Therapeutics AVTX
NASDAQ AVTX
$14.99 +0.04 (+0.27%)
At close: Oct 2, 2026 · 4:00 PM EDT

Avalo Therapeutics (AVTX) Asset Writedowns and Impairment (2018)

Updated

Avalo Therapeutics (AVTX) recorded Asset Writedowns and Impairment of $3.91 million in FY2023.

Analysis

Avalo Therapeutics (AVTX) Asset Writedowns and Impairment (2018) Analysis & Trends

  • Annual Asset Writedowns and Impairment has a five-year compound annual growth rate of 15.5% (FY2018 to FY2023).
  • The FY2023 figure is the lowest annual Asset Writedowns and Impairment since FY2019.
  • Per Business Quant data, AVTX's Asset Writedowns and Impairment was $1.45 million in FY2019 (-23.7%).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Avalo Therapeutics 653.59 Mn 653.59 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2018 38,438.00
Sep 30, 2018 159,687.00
Jun 30, 2018 1.70 Mn
API Access

Avalo Therapeutics Asset Writedowns and Impairment API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=asset-writedowns-and-impairment&ticker=AVTX&period=max&api_key=YOUR_API_KEY